Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study

This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.